Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial
Abstract Background Hormone receptor (HR)-positive, HER2/neu-negative breast cancers have a sustained risk of recurrence up to 20 years from diagnosis. TEAM (Tamoxifen, Exemestane Adjuvant Multinational) is a large, multi-country, phase III trial that randomized 9776 women for the use of hormonal therapy. Of these 2754 were Dutch patients. The current study aims for the first time to correlate the ten-year clinical outcomes with predictions by CanAssist Breast (CAB)—a prognostic test developed in South East Asia, on a Dutch sub-cohort that participated in the TEAM. The total Dutch TEAM cohort... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2023 |
Reihe/Periodikum: | Breast Cancer Research, Vol 25, Iss 1, Pp 1-11 (2023) |
Verlag/Hrsg.: |
BMC
|
Schlagwörter: | CanAssist Breast (CAB) / Early breast cancer / Adjuvant / Endocrine therapy / Distant recurrence / Neoplasms. Tumors. Oncology. Including cancer and carcinogens / RC254-282 |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26626831 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://doi.org/10.1186/s13058-023-01643-2 |